Abdel-Rahman Omar, Fouad Mona
a Clinical Oncology Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
b Medical Microbiology and Immunology Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
Expert Rev Neurother. 2015;15(11):1255-70. doi: 10.1586/14737175.2015.1101346. Epub 2015 Oct 15.
This systematic review aims to assess irinotecan-based salvage regimens for patients with recurrent glioblastoma multiforme (GBM) beyond first line treatment. Eligible trials were identified using databases search and 25 studies were included in the final analysis. Among the 25 studies, PFS-6 rate was reported in 15 studies and it ranged from 16% to 63%. Median PFS was reported in 18 studies and it ranged from 1 to 7.6 months. While for median OS, it was reported in 17 studies and it ranged from 5.8 months to 17.9 months. The available data suggests that routine use of irinotecan-based salvage regimens cannot be recommended outside the setting of well-controlled prospective randomized studies investigating novel combinations of irinotecan.
本系统评价旨在评估以伊立替康为基础的挽救方案用于一线治疗后复发的多形性胶质母细胞瘤（GBM）患者的疗效。通过检索数据库确定符合条件的试验，最终分析纳入了25项研究。在这25项研究中，15项研究报告了6个月无进展生存率（PFS-6），其范围为16%至63%。18项研究报告了中位无进展生存期，范围为1至7.6个月。而中位总生存期方面，17项研究报告了相关数据，范围为5.8个月至17.9个月。现有数据表明，在未开展关于伊立替康新联合方案的严格对照前瞻性随机研究的情况下，不建议常规使用以伊立替康为基础的挽救方案。
